New Haven biotech company Halda Therapeutics reports positive results in preclinical trials of its oral candidate for the treatment of prostate cancer.
Halda is developing a novel class of cancer therapies called RIPTAC (Regulated Induced Proximity TArgeting Chimeras) therapeutics. It works as a novel “hold and kill” mechanism for the precision treatment of cancer, according to the company.